A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaluate the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to Type 2 Diabetes Mellitus in obese and overweight subjects with Cardiovascular Disease or Multiple Cardiovascular risk factors
IRB Number: 014-016
Legacy Heart Center
6601 Preston Road
Plano, TX 75024
Lead Principal Investigator: Marcus McKenzie, MD
|Clinical Study Identifier||TX138930|
|Last Modified on||23 November 2020|
Select a piece of text and start making personal notes.
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.Learn more
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.Learn more
Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.Learn more
Congrats! You have your own personal workspace now.